RESUMEN
PURPOSE: Fear of cancer recurrence (FCR) is common and associated with younger age. This study aimed to explore the prevalence and correlates of FCR amongst younger survivors of early breast cancer. SUBJECTS: A total of 218 women aged 18-45 were diagnosed with stage 0-2 breast cancer at least 1 year earlier. METHODS: The participants completed a web-based survey including a validated measure of FCR and items exploring medical surveillance practices and health care use. RESULTS: A total of 70% of participants reported clinical levels of FCR. Higher FCR was associated with higher frequency of unscheduled visits to the GP, higher frequency of breast self-examination and other forms of self-examination for cancer, not having mammograms or ultrasounds or other forms of cancer screening in the past year, more complementary therapy use and the use of counselling and support groups. CONCLUSIONS: Young women with breast cancer are particularly vulnerable to FCR. The present study provides preliminary evidence that FCR is associated with higher health costs and lower surveillance rates which may compromise health outcomes. Routine screening for FCR in follow-up care is recommended.
Asunto(s)
Neoplasias de la Mama/psicología , Miedo , Conductas Relacionadas con la Salud , Recurrencia Local de Neoplasia/psicología , Adolescente , Adulto , Factores de Edad , Neoplasias de la Mama/patología , Estudios Transversales , Recolección de Datos , Femenino , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Prevalencia , Sobrevivientes/psicología , Adulto JovenRESUMEN
BACKGROUND: The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC. METHODS: The ER+ tumours were classified as 'luminal A' (LA): ER+ and/or PR+, Ki-67 low, p53-, HER2- or 'luminal B' (LB): ER+ and/or PR+and/or Ki-67 high and/or p53+ and/or HER2+. Kaplan-Meier and Cox proportional hazards methodology were used to ascertain relationships to ispilateral breast tumour recurrence (IBTR), locoregional recurrence (LRR), distant metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS). RESULTS: In all, 73 patients previously LA were re-classified as LB: a greater than four-fold increase (4.6-19.3%) compared with ER, PR, HER2 alone. In multivariate analysis, the LB signature independently predicted LRR (hazard ratio (HR) 3.612, 95% CI 1.555-8.340, P=0.003), DMFS (HR 3.023, 95% CI 1.501-6.087, P=0.002) and BCSS (HR 3.617, 95% CI 1.629-8.031, P=0.002) but not IBTR. CONCLUSION: The prognostic evaluation of ER+ breast cancer is improved using a marker panel, which includes Ki-67 and p53. This may help better define a group of poor prognosis ER+ patients with a greater probability of failure with endocrine therapy.
Asunto(s)
Neoplasias de la Mama/diagnóstico , Carcinoma/diagnóstico , Antígeno Ki-67/metabolismo , Receptores de Estrógenos/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/metabolismo , Biomarcadores de Tumor/fisiología , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma/terapia , Terapia Combinada , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Antígeno Ki-67/análisis , Antígeno Ki-67/fisiología , Mastectomía Segmentaria , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Radioterapia Conformacional , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Proteína p53 Supresora de Tumor/análisis , Proteína p53 Supresora de Tumor/fisiologíaRESUMEN
The aim of this study was to audit the results of a high-dose, combined-modality prospective protocol for non-small-cell lung cancer in terms of survival, disease-specific survival and toxicity. One hundred and twenty-one patients with non-small-cell lung cancer were treated with a concurrent, end-phase, boost, high-dose radiotherapy protocol with 65 Gy in 35 fractions for more than 5 weeks. Sixty-six patients received radiotherapy alone (group 1), 29 received concurrent chemoradiation (group 2) and 26 received neoadjuvant and concurrent chemotherapy (group 3). Thirty-four patients had stage I disease, six had stage II and 81 had stage III. Overall median survival was 23 months: 75% at 1 year and 23% at 5 years. Median survivals for patients with stage I and stages II and III disease were 43 and 19 months, respectively. For stages II and III patients by groups 1-3, median survivals were 18, 25 and 18 months, respectively, and 2-year survivals were 36, 52 and 38%, respectively. Toxicity was acceptable. Overall, 9% had symptomatic pneumonitis and 7% had grades 3 and 4 oesophagitis. For those who had the mediastinum included in the volume, grade > or = 3 oesophagitis occurred in 0, 11 and 22% (n = 110, P = 0.001), respectively, for treatment groups 1-3. Overall treatment-related mortality was 3%, consisting of two septic deaths, one pneumonitis and possibly one late cardiac event, all occurring in patients who had chemotherapy (7% of 55 patients). Treatment-related mortality declined over the study period. Accelerated radiotherapy was well tolerated, with only moderate increased acute toxicity when combined with concurrent platinum chemotherapy. Toxicity was enhanced by induction chemotherapy. Overall survival outcomes were excellent for this condition. Continued use of this radiotherapy schedule is recommended as the platform for assessment of other chemotherapy schedules.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Neoplasias Pulmonares/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Distribución de Chi-Cuadrado , Cisplatino/uso terapéutico , Terapia Combinada , Fraccionamiento de la Dosis de Radiación , Femenino , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Neumonitis por Radiación/epidemiología , Dosificación Radioterapéutica , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
AIM: To test the viability of a full-scale randomised comparison of two steroid doses given with radiotherapy for malignant spinal-cord compression (MSCC), to test Internet randomisation and to compare different functional outcome measures. MATERIALS AND METHODS: A log of screened patients at eight recruiting centres was maintained. Patients were randomised via the Superdex website to either 96 mg or 16 mg daily of dexamethasone. Radiotherapy treatment was 30 Gy in 10 fractions. Outcomes assessed used ambulation, Barthel Index ambulation, Functional Independence Measure (FIM) ambulation and Functional Improvement Score (FIS) at 1 month. RESULTS: One hundred and thirty-one patients were screened. Ninety-three (71%) were ineligible, 65% of these were because duration of prior steroid use was greater than 12 h, failure to meet strict definition of magnetic resonance imaging, defined MSCC, multi-level disease or previous spinal-cord compression treatment. Twenty of the 38 eligible patients were randomised, including seven outside standard office hours. There was a high rate of serious adverse events (n = 9), but only one was considered likely to be related to study medication. At baseline, 75% were ambulant, 70% had FIM ambulation scores greater than 5 and 50% had Barthel Index ambulation scores greater than 2. At day 28, including all randomised patients (by scoring four dead patients as non-ambulant), ambulation scores by the various definitions were 60%, 45% and 40%, respectively. For the 16 patients evaluable at day 28, the mean FIS was -1.4. Median survival was 69 days and 1-year survival 13%. CONCLUSION: Web randomisation was successful; however, the high ineligibility rate precludes a full-scale dexamethasone dose trial in Australia. Choice of measure of ambulation has potentially significant effects on outcomes and implications for the design of any future MSCC trials. Referral delays are of concern.
Asunto(s)
Antiinflamatorios/administración & dosificación , Dexametasona/administración & dosificación , Neoplasias/complicaciones , Compresión de la Médula Espinal/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios/efectos adversos , Dexametasona/efectos adversos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Internet , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Selección de Paciente , Proyectos Piloto , Compresión de la Médula Espinal/etiología , Compresión de la Médula Espinal/radioterapia , Tasa de Supervivencia , Resultado del Tratamiento , CaminataRESUMEN
PURPOSE: The use of chemotherapy and endocrine therapies in the treatment of premenopausal women carries with it reproductive and gynecologic implications that young women may find distressing and discordant with plans for childbearing. This multicenter study aimed to investigate fertility- and menopause-related information needs among young women with a diagnosis of early-stage breast cancer. PATIENTS AND METHODS: Two hundred twenty-eight women with a diagnosis of early-stage breast cancer who were aged 40 years or younger at diagnosis and who were 6 to 60 months after diagnosis were entered onto the trial. Participants completed a mailed self-report questionnaire that included a purposely designed fertility- and menopause-related information needs survey and standardized measures of distress, anxiety, quality of life, menopausal symptoms, and information-seeking style. RESULTS: Seventy-one percent of participants discussed fertility-related issues with a health professional as part of their breast cancer treatment, and 86% discussed menopause-related issues. Consultation with a fertility or menopause specialist was the most preferred method of obtaining this information. Receiving fertility-related information was rated as being significantly more important than receiving menopause-related information at time of diagnosis (P < .001) and at treatment decision making (P = .058). Receiving menopause-related information was rated as being significantly more important than receiving fertility-related information during adjuvant treatment (P < .05), at completion of adjuvant treatment (P < .001), and during follow-up (P < .001). Common questions, sources of information, and correlates of perceived importance were identified. CONCLUSION: The results of this study suggest that younger women have unmet needs for fertility- and menopause-related information and provide preliminary empirical data to guide the development of better fertility- and menopause-related patient education materials for younger women with a diagnosis of early breast cancer.
Asunto(s)
Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/terapia , Fertilidad , Menopausia , Evaluación de Necesidades , Adulto , Edad de Inicio , Neoplasias de la Mama/psicología , Femenino , Encuestas de Atención de la Salud , Humanos , Estadificación de Neoplasias , Educación del Paciente como Asunto , Calidad de Vida , Estrés PsicológicoRESUMEN
Two randomized trials have recently shown a statistically significant improvement in local control when a boost is employed in the conservative treatment of early breast cancer. However, unresolved issues of cost effectiveness, potentially increased toxicity and the inability to automatically generalize these results to Australian and New Zealand practice remain. In view of these unresolved controversies, the St George and Wollongong hospitals breast boost trial (SGW trial) will continue to recruit.
Asunto(s)
Neoplasias de la Mama/radioterapia , Anciano , Australia , Relación Dosis-Respuesta en la Radiación , Europa (Continente) , Femenino , Humanos , Nueva Zelanda , Dosificación Radioterapéutica , Radioterapia Adyuvante , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
A case is reported here of delayed presentation of primary testicular seminoma, 9 years after initial presentation with retroperitoneal disease. The diagnostic difficulty associated with primary extragonadal germ cell tumour is emphasized.
Asunto(s)
Neoplasias Retroperitoneales/secundario , Seminoma/diagnóstico , Neoplasias Testiculares/diagnóstico , Adulto , Humanos , Masculino , Seminoma/secundario , Neoplasias Testiculares/patología , Factores de TiempoRESUMEN
A method is described for using substance P (SP) antibodies as an antagonist in the retina of a cyprinid fish, the roach (Rutilus rutilus). Antibody solution (10 microliters) injected into the vitreous was found by immunohistochemical localization to penetrate the neural retina up to the level of the inner margin of the inner nuclear layer. Thus, the inner plexiform layer, where SP would normally be released, was well infiltrated. Similar penetration patterns were observed 2 or 24 h after injection. The physiological effectiveness of the antibody was demonstrated indirectly by measuring its effect upon the spatial coupling of the horizontal cells. Previous work suggested that SP stimulates dopamine release which normally uncouples the horizontal cell somata but not the syncytium of their axon terminals. In retinae isolated from antibody-injected eyes, the horizontal cell somata (but not axon terminals) were indeed found to be significantly more strongly coupled, consistent with the blockage of SP-induced, presumably tonic, release of dopamine. The results suggest that peptide antisera can be useful as pharmacological tools to investigate electrophysiological effects of neuropeptides in the retina as in other parts of the central nervous system.